Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Tafero Em

Tafero Em-Afafenamide

Availability: In stock

Special Price $ 55

BRAND : Tafero Em
STRENGTH : 200mg and 25mg
INGREDIENT : Tafero Em-Afafenamide
COMPANY NAME : Hetero
COUNT : 30 Tablets



Description of Tafero Em

Description: Tafero EM is a fixed dose combination drug, which contains two excellent components like tenofovir Alafenamide fumarate and Emtricitabine Tafero EM is a prescription medicine, used by the patients only under the knowledge of medical practitioner Tenofovir Alafenamide Fumarate & Emtricitabine TAF and Emtricitabine are nucleotide reverse transcriptase inhibitor that involved in suppression of growth of HIV virus associated with AIDS

Pharmacology of Tafero Em

Mechanism of action: TAF (Tenofovir Alafenamide Fumarate) TAF is a novel ester prodrug of anti-retroviral tenofovir, and it is a nucleotide reverse transcriptase inhibitor After an oral administration, TAF is transformed into tenofovir Tenofovir (acyclic nucleoside phosphonate analog of adenosine 5 monophosphate) Tenofovir depletes DNA binding, there is a lack of 3 OH molecules (water molecules are responsible for phosphodiester bond linkage) By opposing the regular nucleotide for insertion into proviral DNA and blockade of formation of 5 to 3 phosphodiester linkage which is needed for DNA elongation Tenofovir leads to chain termination and block proviral DNA transcription Emtricitabine: Emtricitabine is one of the components of Tafero EM; it exhibits its anti-retroviral activity by inhibiting reverse transcriptase, the enzyme which is responsible for transcript HIV RNA into new viral DNA. Emtricitabine is phosphorylated to Emtricitabine 5 phosphate with the help of cellular enzymes Emtricitabine 5 phosphates is HIV-1 reverse transcriptase inhibitor Emtricitabine 5 phosphates fight with deoxycytidine 5 triphosphate (natural substrate) and inserted into viral DNA causes chain termination Pharmacokinetics: Absorption: Tafero EM; the absorption of tenofovir is occur fastly and its Tmax is observed at 1 hour after administration; whereas Emtricitabine is absorbed rapidly and its mean bioavailability is 93% Distribution: The human plasma protein bound of Emtricitabine is very low less than 4% Tenofovir is highly bound to human plasma protein with the range of 80% Metabolism: TAF, is hydrolyzed into tenofovir within the cells, it is the major metabolite again phosphorylated into tenofovir diphosphate active metabolite Emtricitabine is metabolized minimally and it is found in urine as unchanged form Elimination: The route of elimination mostly through urine The terminal half life of Emtricitabine is 10 hours The terminal half life period of tenofovir is 0.51 hour

Indication of Tafero Em

Brand: Tafero EM Active components: Tenofovir Alafenamide Fumarate and Emtricitabine Strength of the components: 25MG & 200MG respectively Mfg: Hetero labs Pack: 30 tablets in a container Classification: Anti-retroviral drug. Tafero EM, a combination tablet contains tenofovir Alafenamide fumarate and Emtricitabine is mainly indicated for the treatment of HIV-1 infection in adult’s patients.

Dose & Dosage's of Tafero Em

The prescribed dose of Tafero EM in the condition of HIV-1 infection in adults is, one tablet should be taken once daily with or without food. In Pre-exposure Prophylaxis: uninfected adults should take one tablet orally as a single dose. Missed dose: If patient fail to take the dose of Tafero EM tablet, must consult with medical practitioner To avoid overdose toxicity problems, skipped the missed dose and follow the regular dosing schedule Do not take double dose

Side Effects of Tafero Em

General: Diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal drms Metabolic: Increased fasting cholesterol, decreased phosphorus, increased fasting triglycerides, altered serum glucose, weight loss, hyperglycemia, increased alkaline phosphatase, lactic acidosis severe hepatomegaly Hepatic: Increased AST and ALT, hepatic steatosis, lactic acidosis, increased bilirubin, severe acute exacerbation of hepatitis B Blood: Decreased neutrophils and hemoglobulin Respiratory: Pharyngitis, sinusitis, upper respiratory tract infection, Nasopharyngitis, increased cough, pneumonia, rhinitis Gastrointestinal: Increased serum amylase, abdominal pain, pancreatitis, increased serum lipase Psychiatric: Depression, insomnia, anxiety Nerve system: Headache, somnolence, peripheral neuropathy Others: Fatigue, syphilis, pain, fever, asthenia, high vitamin D levels Skin: Rashes, skin discoloration, lipodystrophy, angioedema, sweating Genitourinary: Proteinuria, urethritis, urinary tract infection, Hematuria, genital ulceration, anogenital warts Polyuria, glycosuria Immune: Immune reconstitution/reactivation syndrome, autoimmune disorders Hypersensitivity: Allergic reaction Endocrine: High serum parathyroid hormones

Contraindication of Tafero Em

Tafero EM should not be used in persons with unknown or positive 1 status. Tafero EM not used as monotherapy, it is used with other retroviral medicine. Hypersensitivity in lactation

Drug Interaction of Tafero Em

Acyclovir-valaciclovir: increase the serum concentration of tenofovir Adefovir: decrease the therapeutic effect of tenofovir Amino glycosides: increase the serum concentration of tenofovir Carbamazepine: decrease the serum concentration of tenofovir Cidofovir: increase the serum concentration of tenofovir Cobicistat: may increase the toxic effects of tenofovir Diclofenac: may enhance the nephrotoxicity effect of tenofovir Fosphenytoin/phenytoin: decrease the serum concentration of tenofovir Lamivudine: increase toxic effects of Emtricitabine NSAIDS: increase the nephrotoxicity effect of tenofovir Orlistat: decrease the serum concentration of anti-retroviral drugs Oxcarbazepine, Phenobarbital, primidone, rifabutin, rifampin, rifapentine, st. Johns wort, tipranavir these are the drugs which involved in depletion of serum concentration of tenofovir

Precaution of Tafero Em

Tafero EM should be used cautiously, during the therapy some of adverse effects occur; Immune reconstitution syndrome Lactic acidosis Hepatomegaly with steatosis Renal toxicity Acute or severe exacerbations of HBV occurs during discontinuation of anti-retroviral therapy Renal impairment

Usage & Safety profile of Tafero Em Pregnancy & Lactation

Pregnancy category: B Tafero EM should be used cautiously, it is recommended for limited number for pregnancy In case of any deformity, Tafero EM should not suggested for pregnancy condition or women who become pregnant Breast feeding is not recommended

Storage of Tafero Em

Tafero EM tablet container should be stored below 30oC (86oF) Container should be keep away from moisture, heat and light